Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.

Also called NCT04133168

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 458 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04133168
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, France, Germany, Hong Kong SAR China, Italy, Netherlands, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04133168. Allocation not applicable; no masking; primary purpose treatment. Start 2020-06-24 (actual); primary completion 2022-11-10 (actual). Results posted on 2023-12-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation
Acronym
FROZEN-AF
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
Boston Scientific Cardiac Cryoablation System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct04133168
Content hash
b91ebc9290b8343d2e1ca01a543410a156a6831564f058db4740b6436bdd05b8